IMMUNORADIOMETRIC ASSAY OF PRO-CATHEPSIN-D IN BREAST-CANCER CYTOSOL - RELATIVE PROGNOSTIC VALUE VERSUS TOTAL CATHEPSIN-D

被引:34
作者
BROUILLET, JP
SPYRATOS, F
HACENE, K
FAUQUE, J
FREISS, G
DUPONT, F
MAUDELONDE, T
ROCHEFORT, H
机构
[1] INSERM,U148,UNITE HORMONES & CANC,60 RUE NAVACELLES,F-34090 MONTPELLIER,FRANCE
[2] CHU MATERNITE,F-34059 MONTPELLIER,FRANCE
[3] CTR RENE HUGUENIN,F-92210 ST CLOUD,FRANCE
[4] CIS BIOINT,LAPAM,CTR MARCOULE,F-30205 BAGNOLS SUR CEZE,FRANCE
关键词
D O I
10.1016/0959-8049(93)90066-O
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In breast cancer cell lines, the maturation of pro-cathepsin D into enzymatically active cathepsin D is altered, leading to its increased secretion. In order to specifically assay pro-cathepsin D (52 kD form) in breast cancer cytosol, we monitored a solid phase sandwich radioimmunoassay using D9H8 and D7E3 monoclonal antibodies raised against human pro-cathepsin D from MCF7 cells. Pro-cathepsin D was assayed in 108 primary breast cancer cytosols in which total cathepsin D was previously found to be correlated with metastasis. Pro-cathepsin D concentrations were found to be correlated with total cathepsin D and with lymph node invasion, and was slightly higher in premenopausal patients. By contrast, Cox multiparametric analysis showed that pro-cathepsin D status had no prognostic value for survival, or metastasis free survival contrary to total cathepsin D status. This first study shows the technical validity of the pro-cathepsin D assay but indicates that it has less value as a prognostic marker than total cathepsin D. This study also shows that the proportion of pro-cathepsin D recovered in vivo (1-6%) is much less than that produced in cell lines and suggests that the secreted pro-enzyme might be activated in the tumour extracellularly or following its reinternalisation.
引用
收藏
页码:1248 / 1251
页数:4
相关论文
共 16 条
[1]  
BRIOZZO P, 1988, CANCER RES, V48, P3688
[2]   CATHEPSIN D ASSAY IN PRIMARY BREAST-CANCER AND LYMPH-NODES - RELATIONSHIP WITH C-MYC, C-ERB-B-2 AND INT-2 ONCOGENE AMPLIFICATION AND NODE INVASIVENESS [J].
BROUILLET, JP ;
THEILLET, C ;
MAUDELONDE, T ;
DEFRENNE, A ;
SIMONYLAFONTAINE, J ;
SERTOUR, J ;
PUJOL, H ;
JEANTEUR, P ;
ROCHEFORT, H .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) :437-441
[3]   INCREASED PLASMA CATHEPSIN-D CONCENTRATION IN HEPATIC CARCINOMA AND CIRRHOSIS BUT NOT IN BREAST-CANCER [J].
BROUILLET, JP ;
HANSLICK, B ;
MAUDELONDE, T ;
PIVAT, MT ;
GRENIER, J ;
BLANC, F ;
ROCHEFORT, H .
CLINICAL BIOCHEMISTRY, 1991, 24 (06) :491-496
[4]  
CAPONY F, 1989, CANCER RES, V49, P3904
[5]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[6]  
FREISS G, 1988, CANCER RES, V48, P3709
[7]  
GARCIA M, 1985, CANCER RES, V45, P709
[8]   LYSOSOMAL-ENZYME PRECURSORS IN HUMAN-FIBROBLASTS - ACTIVATION OF CATHEPSIN-D PRECURSOR INVITRO AND ACTIVITY OF BETA-HEXOSAMINIDASE-A PRECURSOR TOWARDS GANGLIOSIDE GM2 [J].
HASILIK, A ;
VONFIGURA, K ;
CONZELMANN, E ;
NEHRKORN, H ;
SANDHOFF, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1982, 125 (02) :317-321
[9]   INTERACTIONS OF CATHEPSIN-D AND INSULIN-LIKE GROWTH FACTOR-II (IGF-II) ON THE IGF-II MANNOSE-6-PHOSPHATE RECEPTOR IN HUMAN BREAST-CANCER CELLS AND POSSIBLE CONSEQUENCES ON MITOGENIC ACTIVITY OF IGF-II [J].
MATHIEU, M ;
ROCHEFORT, H ;
BARENTON, B ;
PREBOIS, C ;
VIGNON, F .
MOLECULAR ENDOCRINOLOGY, 1990, 4 (09) :1327-1335
[10]  
MAUDELONDE T, 1989, CANCER, V63, P1265, DOI 10.1002/1097-0142(19890401)63:7<1265::AID-CNCR2820630706>3.0.CO